Table 1. Transthoracic echocardiography in T. cruzi-infected (± resveratrol or SRT1720 treatment) mice.
| Parameters | Mode | WT | WT x T. cruzi | a Resveratrol x | b SRT1720 x |
|---|---|---|---|---|---|
| T. cruzi | |||||
| T. cruzi | |||||
| Heart rate (HR, beats per minute) | B mode | 472 ± 51 | 464 ± 44 | 523± 63 | 489± 30 |
| End systolic volume (ESV, μl) | B mode | 16.56± 3.93 | 37.16± 2.82*** | 24.14± 2.95### | 24.07± 0.83### |
| End diastolic volume (EDV, μl) | B mode | 55.22± 7.72 | 51.42± 6.88 | 53.82± 7.26 | 58.65± 2.94 |
| Stroke volume (SV = EDV–ESV, μl) | M mode | 47.96± 2.08 | 29.60± 3.72*** | 39.88± 4.29# | 38.11± 3.47# |
| Cardiac output (HR x SV, ml/min) | M mode | 17.25± 2.76 | 8.52± 2.75*** | 15.60± 3.83# | 12.66± 0.41# |
| % Ejection fraction (% EF = EDV-ESV x 100 / EDV) | M mode | 65.78± 6.31 | 41.50± 5.60*** | 49.90± 8.47 | 55.48± 4.46# |
| LVID, end systole (LVIDs, mm) | M mode | 1.48± 0.21 | 3.16 ± 0.21*** | 3.18± 0.62 | 2.55± 0.66 |
| % Fractional shortening (% FS = (LVIDd−LVIDs) x 100 / LVIDd | M mode | 34.95± 5.24 | 22.44± 1.46*** | 21.41± 3.29 | 24.13 ± 2.67# |
| Interventricular septum (IVSs, mm) | M mode | 0.84 ± 0.23 | 1.21 ± 0.22* | 0.82 ± 0.16 | 1.25 ± 0.21 |
| IVSd, mm | M mode | 0.62± 0.14 | 1.04±0.20*** | 0.89± 0.13 | 0.79±0.19 |
| LV posterior wall (LVPWs, mm) | M mode | 1.45±0.30 | 0.85± 0.14*** | 0.97± 0.22 | 1.18± 0.21 |
| LVPWd, mm | M mode | 0.92± 0.17 | 0.67± 0.13* | 0.86± 0.09 | 0.78± 0.23 |
| IVSs / LVPWs ratio | M mode | 0.59± 0.15 | 1.4± 0.37*** | 1.21± 0.25 | 0.94± 0.14 |
| Area systole (mm2) | B mode | 11.29± 2.67 | 15.77± 3.29* | 10.48± 1.07 | 10.38± 0.67# |
| Area diastole (mm2) | B mode | 17.67± 2.72 | 24.07±5.88* | 16.36± 0.89 | 17.02± 1.46 |
| LV mass (mg) | M mode | 69.91± 10.44 | 97.86± 11.54*** | 73.53± 4.35 | 91.66± 3.04 |
C57BL/6 mice were infected with T. cruzi (10,000 parasites per mouse).
a Mice were treated with resveratrol (20 mg/L) in drinking water during days 90-111post-infection (pi).
b Mice were treated with SRT1720 (1 mg/mouse, intraperitoneal) during days 45–66 pi. Treatment was given three times a week.
Transthoracic echocardiography was performed in B and M mode at ~150 days post-infection using a Vevo 2100 System.
Data are presented as mean value ± SD. Significance is plotted as *normal vs. infected and #WT.Tc vs. WT.Tc + treatment, and presented as *,# <0.05, **,## p<0.01, ***,### p<0.001 (n = 6–10 per group per experiment).